FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221112258> ?p ?o ?g. }

• W4221112258 endingPage "08" @default.
• W4221112258 startingPage "P4" @default.
• W4221112258 abstract "Abstract Nearly 70% of newly diagnosed cases of breast cancer (BC) are estrogen receptor positive (ER+) where endocrine therapy is a primary treatment. Despite initial efficacy seen with endocrine therapies, approximately 40% of patients develop acquired resistance which ultimately limits the use of these agents even as most of these tumors continue to require ERα. The strategies to combat these cancers with resistance are not yet defined and represent the next major clinical challenge in ER+ breast cancer. Amcenestrant is an optimized oral SERD (selective estrogen receptor degrader) with potent antagonist and degradation activity irrespective of ESR1 mutational status, and is currently being evaluated as monotherapy and in combination with CDK4/6 inhibitors and other targeted therapies for ER+ breast cancer patients in clinical trials. Here, we report that in preclinical models, amcenestrant achieved significant anti-tumor efficacy/regression as a monotherapy and strong synergistic activity when administered together with the CDK4/6 inhibitor, palbociclib, in subcutaneously xenografted endocrine resistant ER+ BC mouse models: ESR1-Y537S mutant-driven MCF7 tumor and HCI-013 PDX (patient-derived xenograft). Transcriptional profile analysis of xenograft tumor biopsies revealed the modulation of different pathways by SERD and palbociclib and highlighted crosstalk of ER and CDK4 signaling pathways. Interestingly, CDK4/6 inhibition by palbociclib induces partial activation of ER pathways as potential mechanism of tumor escape which is completely abolished by the combination treatment of amcenestrant with palbociclib. Early clinical data also showed that amcenestrant in combination with palbociclib, exhibited a favorable safety profile and encouraging antitumor activity in patients with endocrine resistant, ER+/HER2-, advanced breast cancer, which supports its potential to become a new endocrine backbone therapy for ER+ HER2- breast cancer. In conclusion, amcenestrant is an oral SERD, which exhibits significant anti-tumor activity as a single agent and shows synergistic activity with CDK4/6 inhibitor palbociclib in ER+ BC xenografts preclinically and in early clinical development. Citation Format: Maysoun Shomali, Zhuyan Guo, Jane Cheng, Amy Sullivan, Youssef El-Ahmad, Fangxian Sun, Sukhvinder Sidhu, Joon Sang Lee, Hui Cai, Jack Pollard, Laurent Debussche, Chris Soria, Monsif Bouaboula. Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-02-08." @default.
• W4221112258 created "2022-04-03" @default.
• W4221112258 creator A5001799694 @default.
• W4221112258 creator A5004877142 @default.
• W4221112258 creator A5005153959 @default.
• W4221112258 creator A5010553215 @default.
• W4221112258 creator A5018300249 @default.
• W4221112258 creator A5019924343 @default.
• W4221112258 creator A5028072650 @default.
• W4221112258 creator A5037976011 @default.
• W4221112258 creator A5050180985 @default.
• W4221112258 creator A5050555159 @default.
• W4221112258 creator A5052089394 @default.
• W4221112258 creator A5057539471 @default.
• W4221112258 creator A5080531373 @default.
• W4221112258 date "2022-02-15" @default.
• W4221112258 modified "2023-10-14" @default.
• W4221112258 title "Abstract P4-02-08: Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models" @default.
• W4221112258 doi "https://doi.org/10.1158/1538-7445.sabcs21-p4-02-08" @default.
• W4221112258 hasPublicationYear "2022" @default.
• W4221112258 type Work @default.
• W4221112258 citedByCount "0" @default.
• W4221112258 crossrefType "journal-article" @default.
• W4221112258 hasAuthorship W4221112258A5001799694 @default.
• W4221112258 hasAuthorship W4221112258A5004877142 @default.
• W4221112258 hasAuthorship W4221112258A5005153959 @default.
• W4221112258 hasAuthorship W4221112258A5010553215 @default.
• W4221112258 hasAuthorship W4221112258A5018300249 @default.
• W4221112258 hasAuthorship W4221112258A5019924343 @default.
• W4221112258 hasAuthorship W4221112258A5028072650 @default.
• W4221112258 hasAuthorship W4221112258A5037976011 @default.
• W4221112258 hasAuthorship W4221112258A5050180985 @default.
• W4221112258 hasAuthorship W4221112258A5050555159 @default.
• W4221112258 hasAuthorship W4221112258A5052089394 @default.
• W4221112258 hasAuthorship W4221112258A5057539471 @default.
• W4221112258 hasAuthorship W4221112258A5080531373 @default.
• W4221112258 hasConcept C121608353 @default.
• W4221112258 hasConcept C126322002 @default.
• W4221112258 hasConcept C143998085 @default.
• W4221112258 hasConcept C172313692 @default.
• W4221112258 hasConcept C2775930923 @default.
• W4221112258 hasConcept C2776999253 @default.
• W4221112258 hasConcept C2777164284 @default.
• W4221112258 hasConcept C2779744173 @default.
• W4221112258 hasConcept C2780482068 @default.
• W4221112258 hasConcept C502942594 @default.
• W4221112258 hasConcept C530470458 @default.
• W4221112258 hasConcept C71924100 @default.
• W4221112258 hasConcept C84606932 @default.
• W4221112258 hasConcept C98274493 @default.
• W4221112258 hasConceptScore W4221112258C121608353 @default.
• W4221112258 hasConceptScore W4221112258C126322002 @default.
• W4221112258 hasConceptScore W4221112258C143998085 @default.
• W4221112258 hasConceptScore W4221112258C172313692 @default.
• W4221112258 hasConceptScore W4221112258C2775930923 @default.
• W4221112258 hasConceptScore W4221112258C2776999253 @default.
• W4221112258 hasConceptScore W4221112258C2777164284 @default.
• W4221112258 hasConceptScore W4221112258C2779744173 @default.
• W4221112258 hasConceptScore W4221112258C2780482068 @default.
• W4221112258 hasConceptScore W4221112258C502942594 @default.
• W4221112258 hasConceptScore W4221112258C530470458 @default.
• W4221112258 hasConceptScore W4221112258C71924100 @default.
• W4221112258 hasConceptScore W4221112258C84606932 @default.
• W4221112258 hasConceptScore W4221112258C98274493 @default.
• W4221112258 hasIssue "4_Supplement" @default.
• W4221112258 hasLocation W42211122581 @default.
• W4221112258 hasOpenAccess W4221112258 @default.
• W4221112258 hasPrimaryLocation W42211122581 @default.
• W4221112258 hasRelatedWork W2135944809 @default.
• W4221112258 hasRelatedWork W2751810360 @default.
• W4221112258 hasRelatedWork W2754339892 @default.
• W4221112258 hasRelatedWork W2881463645 @default.
• W4221112258 hasRelatedWork W3083148719 @default.
• W4221112258 hasRelatedWork W3093743109 @default.
• W4221112258 hasRelatedWork W3203690439 @default.
• W4221112258 hasRelatedWork W4206711305 @default.
• W4221112258 hasRelatedWork W4282924254 @default.
• W4221112258 hasRelatedWork W4308437124 @default.
• W4221112258 hasVolume "82" @default.
• W4221112258 isParatext "false" @default.
• W4221112258 isRetracted "false" @default.
• W4221112258 workType "article" @default.